Recently, poly adenosine diphosphate ribosyl (PARP) inhibitors have been incorporated and have shown significant outcome benefits in patients with pathogenic/likely pathogenic BRCA1/2 variants/mutations and high-risk HER2-negative breast cancer [17,18,19]. This evidence concerns the gene ERBB2 and breast carcinoma.